It appears that the Chinese yuan, drug makers and investment banks caught the attention of traders Tuesday -- at least, that's what they're searching for.

If you want to know what stocks traders are interested in right now at this very second, you need look no further than what's hot in Google.

Here's what's hot today.

Analyst Upgrades

• Citigroup upgraded FMC Technologies (FTI) to buy from hold, citing pent-up deepwater drilling demand and valuation. Despite upgrading, the firm lowered its target for shares to $69 from $77.
• Piper Jaffray upgraded Valeant (VRX) to overweight from neutral following the company's merger with Biovail (BVF) and raised its target for shares to $53 from $43.
• Deutsche Bank upgraded Lincare Holdings (LNCR) to buy from hold, citing valuation and the company's dividend initiation. The firm upped its target for shares to $37 from $35.
• Ariba (ARBA) was upgraded to overweight from neutral at JPMorgan.
• Crucell (CRXL) was upgraded to buy from hold at RBS.
• ENI SpA (E) was upgraded to buy from neutral at Goldman.

Analyst Upgrades

• SunTrust upgraded Lennox (LII) to buy from neutral, given signs of improved residential HVAC equipment and service demand and a bottom in commercial lines. The firm has a $55 price target on the stock.
• Cowen upgraded Universal Display (PANL) to outperform from neutral. The firm expects OLED display growth to accelerate driven by increased handset and other mobile device penetration, followed by high-end TV and lighting applications.
• Canaccord upgraded Amylin (AMLN) to hold from sell following Roche's (RHHBY) delay in its Phase 3 study for taspo, a competitor to Amylin's bydureon. The firm has an $18 target on Amylin shares.
• DiamondRock Hospitality (DRH) was upgraded to buy from hold at Citigroup.
• Public Service (PEG) was upgraded to conviction buy from buy at Goldman.
• QuinStreet (QNST) was upgraded to overweight on valuation at Thomas Weisel.

Analyst upgrades:

• Wachovia upgraded shares of Exelon (NYSE: EXC) to Outperform from Market Perform to reflect the company's attractive nuclear fleets and strong operational track record.
  
• Jesup & Lamont upgraded Ormat Technologies Inc. (NYSE: ORA) to Buy from Hold on valuation and increasing visibility on near-term Products revenue.
  
• RBC Capital upgraded Memc Electronic (NYSE: WFR) to Outperform from Sector Perform on expectations of improved demand growth following the likely eight-year extension of the US solar tax credit program.
• AmBev (NYSE: ABV) was raised to Outperform from Neutral at Credit Suisse.
  
• AmerisourceBergen (NYSE: ABC) was upgraded at Merrill Lynch to Buy from Neutral.
  
• Piper upgraded Anadys Pharma (NASDAQ: ANDS) to Neutral from Sell.

Analyst downgrades:

MOST NOTEWORTHY: Telefonica, Affymax and Hatteras Financial were today's noteworthy initiations:

• Deutsche Bank initiated Telefonica (NYSE: TEF) with a Buy rating and believes concerns of an economic slowdown in Spain are overdone and that company is on track to make 2008 guidance.
  
• Baird assumed coverage of Affymax (NADAQ: AFFY) with an Outperform rating and $25 target. The firm believes the market has discounted the regulatory and commercial prospects of lead compound Hematide, which they believe is a $800M revenue opportunity, and recommends buying shares aggressively in the mid-$20s.
  
• Shares of Hatteras Financial (NYSE: HTS) were started with an Outperform rating and $35 target at Friedman Billings. The firm believes management has the opportunity to stabilize its agency portfolio and generate a return on invested capital of about 20%.

OTHER INITIATIONS:

• Caris assumed OmniVision (NASDAQ: OVTI) with a Buy rating and $15 target.
  
• Pioneer Natural (NYSE: PXD) was initiated at UBS with a Buy rating and $110 target.
  
• UBS also initiated CME Group (NYSE: CME) with a Neutral rating and $430 target.
  
• Allied Capital (NYSE: ALD) was assumed with a Buy rating and $14.40 target at Merrill Lynch.

MOST NOTEWORTHY: Marvel Entertainment Inc (MVL) and Affymetrix Inc (AFFY) were today's most notable initiations:

• Sanders Morris started Marvel Entertainment Inc (NYSE: MVL) with a Buy rating and $34 target on the belief that 2007 guidance is conservative.

• Thomas Weisel initiated Affymetrix Inc (NASDAQ: AFFY) with an Overweight rating and is positive on Hematide, their lead drug, to treat anemia.

OTHER INITIATIONS:

• Morgan Stanley initiated Emmis Communications Corp (NASDAQ: EMMS) with an Equal-Weight rating and $10 target.

• Nollenberger started LSI Logic Corp (NYSE: LSI) with a Neutral rating and $10 target; they believe it will take several quarters for the LSI-Agere business plan to pan out.

• Morgan Keegan believes shares of Buffalo Wild Wings Inc (NASDAQ: BWLD) are fairly valued, starting the company with a Market Perform rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).